Akums Expands Access to Eurasian Pharma Markets

Akums Drugs & Pharmaceuticals Ltd. has said that its Hormonal Manufacturing Plant has received a Good Manufacturing Practice (GMP) Certificate from the (BEAEU), this certificate is a key to better access to controlled foreign markets, as well as signifying a step forward in their worldwide production reliability.

The permit is accompanied by hormonal tablets production for oral use, among which is combined oral contraceptives, progestin-only pills, and hormone replacement therapy (HRT) formulations. The products range is closely tied with the women’s health care and endocrine areas, which, in fact, are the most sources of implementation of the research projects in these fields like contraception and menstrual disorders, and hormonal deficiencies and menopause care.

The certification of Akums shall maintain the institution eligible for any of the five EAEU member states - Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan. As a result of the initiative, the registration process is under progress in Russia and Kyrgyzstan and the plan for phased expansion across the bloc has been outlined.

Also Read: Indian Healthcare Sees Breakthroughs with AI in Imaging

Speaking about the results, Sandeep Jain, Managing Director, Akums, remarked, "Our Hormonal Plant’s EAEU GMP certification is a fantastic achievement, especially given that the demand for hormonal therapies in the region is rising continuously. What sets us apart is being able to marry the huge manufacturing capacity with our rigorous quality standards. This certificate authorizes us to play such a part in that increase responsibly, by providing standardized and compliant hormonal formulations for the whole EAEU bloc."